TABLE 3.
Summary of the vaccination based on peptide clinical trials on breast cancer patients. (de Paula Peres et al., 2015).
| Vaccine | Peptide | Gene | Sequence | Target(protein) |
|---|---|---|---|---|
| NeuVax TM | E75(nelipepimut-S) | HER2 | KIFGSLAFL | Her-2/neu |
| GP2 | HER2 | IISAVVGIL | Her-2/neu | |
| AE37 | HER2 | LRMKGVGSPYVSRLLGICL | Her-2/neu | |
| Depovax TM (DPX-0907) | P3 | BAP31 | KLDVGNAEV | BAP31/CDMproteinTopoisomeraseII a |
| P4 | TOP2A | FLYDDNQRV | Integrin β8subunitprecursorAbl-bindingprotein 3CTACE/ADAM-17 | |
| P5 | ITGB8 | ALMEQQHYV | JunctionplakoglobinEDDRI | |
| P7 | ABI_2 | ILDDIGHGV | ||
| P13 | ADA17 | YLIELIDRV | ||
| P14 | JUP | NLMEQPIKV | ||
| P15 | DDR1 | FLAEDALNTV | ||
| MUC1-KLH conjugate plus QS-21 | MUC1 | KLH-MBS-CVTSAPDTRPAPGSTAPPAHGVTSAPDTRPA | Mucin-1 | |
| Oxidized mannan-MUC1 (MFP) | MUC1 | PDTRPAPGSTAPPAHGVTSA | Mucin-1 | |
| Stimuvax | L-BLP25 | MUC1 | STAPPAHGVTSAPDTRPAPGSTAPP | Mucin-1 |